Insulin-like growth factor I (CA) repeats are associated with higher melanoma's Breslow index but not associated with the presence of the melanoma. A pilot study

Santonocito, Concetta; Paradisi, Andrea; Capizzi, Rodolfo; Concolino, Paola; Lavieri, Maria Michela; Silveri, Sara Lanza; Luca, Danièle De; Catricalà, Caterina; Carlo, Aldo Di; Zuppi, Cecilia; Ameglio, Franco; Capoluongo, Ettore

doi:10.1016/j.cca.2008.01.006

Cited by 9 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, our findings are consistent with the only other study of IGF hormones and melanoma (13), which found lower mean serum IGF-I concentrations for cases than controls (p=0.01) and a difference in circulating IGF-I concentration in relation to tumor location (p<0.001). They reported average IGF-I concentrations that were lower in subjects with tumors on the upper limbs and face compared to those with melanoma on the lower limbs and trunk (13). Similarly, we found lower IGF-I levels for patients with melanoma on the face compared to those with melanoma on the trunk.…”

Section: Discussionsupporting

confidence: 92%

“…The authors found that IGF-I serum concentrations were lower in cases than controls (p=0.01); and although the distribution of the 19-CA polymorphic repeat in the IGF-I gene did not differ by case-control status, it was associated with melanoma thickness (Breslow index) (13). The evidence for a role of IGFBP-3 in malignant melanoma is even less clear.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels with risk of malignant melanoma

Park

Setiawan

Kanetsky

et al. 2011

Cancer Causes Control

View full text Add to dashboard Cite

We examined the relationship of insulin-like growth factor-I (IGF-I) and its primary growth factor, IGF binding protein-3 (IGFBP-3) with malignant melanoma using interview data and sera from cases (n=286) and controls (n=289) in a population-based case-control study conducted in 1986–1992 on Oahu, Hawaii. Serum IGF-I and IGFBP-3 concentrations were measured by ELISA. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by unconditional logistic regression and adjusted for age, sex, education, number of blistering sunburns, ability to tan, hair color, energy intake, BMI, height, smoking status, and drinking status. An inverse relationship was found between IGF-I concentration and melanoma (OR for upper vs. lower tertile: 0.44, 95% CI: 0.25–0.79), but clear associations were not observed between malignant melanoma and upper tertiles of IGFBP-3 and the IGF-1:IGFBP-3 molar ratio. The inverse association with IGF-I was strongest among subjects who did not report a history of non-melanoma skin cancer (NMSC) (OR for ≥ vs. < median: 0.39, 95% CI: 0.24–0.65), and a positive association was found among those with such a history (OR: 3.6, 95% CI: 1.0–13; pinteraction=0.0035). Our findings observed here between serum IGF-I and malignant melanoma warrants replication in studies with a larger sample size and a prospective design.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 98%

Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels with risk of malignant melanoma

Park

Setiawan

Kanetsky

et al. 2011

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…A strong association between melanoma severity (expressed as Breslow index) and the IGF-1(CA) 19 repeat frequency was previously found. 50 Concomitantly, serum IGF-1 concentrations were mainly reduced in indi- 19 melanoma. Therefore, these results may have been obtained at diagnosis when melanoma was already present, suggesting that these concentrations could be a consequence of the cancer and its inflammatory component (generally decreased levels) 50 rather than a predisposition marker of tumor development (increased levels).…”

Section: Melanoma and Cell Proliferation Effects By Igf-1mentioning

confidence: 98%

“…50 Concomitantly, serum IGF-1 concentrations were mainly reduced in indi- 19 melanoma. Therefore, these results may have been obtained at diagnosis when melanoma was already present, suggesting that these concentrations could be a consequence of the cancer and its inflammatory component (generally decreased levels) 50 rather than a predisposition marker of tumor development (increased levels). 50 For the first time to my knowledge, serum IGF-1 levels were lower in patients with melanoma than in controls matched for age, sex, eye color, skin type, and body mass index.…”

Section: Melanoma and Cell Proliferation Effects By Igf-1mentioning

confidence: 98%

Insulin-Like Growth Factor System and Sporadic Malignant Melanoma

Capoluongo¹

2011

The American Journal of Pathology

Self Cite

View full text Add to dashboard Cite

Insulin and insulin-like growth factors (IGFsMelanoma is a malignant tumor originating from melanocytes, the melanin-producing cells.1,2 During fetal development, melanocytes migrate to different body areas, such as the skin, uvea, leptomeninges, and mucous membranes (eg, upper esophagus, vulva, and anus).2 Although melanoma may arise in all these sites, cutaneous melanoma is by far the most frequent type of melanoma, representing approximately 5% to 7% of all skin malignancies and the most lethal skin cancer (approximately 75% of all deaths from skin tumors).2,3 The following melanoma risk factors have been extensively described: i) sun exposure, ii) presence of dysplastic nevi, iii) age, iv) ethnicity, v) personal or family history of melanoma, vi) phototype, vii) presence of xeroderma pigmentosum, viii) Li-Fraumeni syndrome, ix) hereditary retinoblastoma history, and x) immunosuppressive conditions. 4 In addition to environmental and individual risk factors, the genetic pedigree may also represent a further risk factor for melanoma development; indeed, multiple differences between melanoma cell genomes and those of normal melanocytes were identified in genomewide analysis studies. In particular, point mutations, deletions, gene amplifications and translocations, and/or epigenetic modifications (eg, promoter hypermethylation) appear to be associated with a significant growth advantage, as opposed to normal skin cells. 5 Furthermore, many molecular changes have been reported in advanced stages of melanoma, as opposed to normal melanocytes. The most common mutations are as follows: i) protoncogene serine/threonine kinase B-Raf-activating mutations, 6 ii) E-cadherin expression silencing, 7 and iii) telomerase activity acquisition, 8 followed by hundreds more, identified by comparative gene expression profiling of melanomas with various American Joint Committee on Cancer stages. 1,9,10 A recent article by Bennet 1 provided a detailed list of possible genes involved in melanoma spreading and development.Along with all pathways and molecules studied in different cancers, including melanoma itself, the study of the insulin-like growth factor (IGF) network of ligands, cell surface receptors, and IGF-binding proteins (IGFBPs; eg, the IGF-1 system) have attracted considerable interest because these pathways play important roles at multiple levels, from cellular and organ to organism.11-13 The IGF system mediates growth, differentiation, and developmental processes; it is involved in a variety of metabolic activities.13 Deregulation of IGF system expression and action is linked to several pathological features, ranging from growth deficits to cancer development. TarSupported by the Italian Health Ministry (code ONC_ORD3207) and Programma strategico 3: Diagnostica ad elevata complessità e tecnologie per il monitoraggio di pazienti con patologie croniche-PROGETTO 4_ISS.Accepted for publication August 10, 2010. CME Disclosure: The author did not disclose any relevant financial relationships.Address reprint requests to Ettor...

show abstract

“…Three case–control studies have examined the relationship between circulating IGF‐I concentrations and risk of melanoma, but the results were not consistent. One study found an inverse relationship between circulating IGF‐I concentration and risk of melanoma, but two studies found an positive association . The results of case–control studies may be unreliable if the development of melanoma affects circulating IGF‐I concentrations, or if bias was introduced in the selection of controls .…”

Section: Introductionmentioning

confidence: 99%

Circulating insulin‐like growth factor I in relation to melanoma risk in the European prospective investigation into cancer and nutrition

Bradbury

Appleby

Tipper

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

Insulin-like growth factor (IGF-I) regulates cell proliferation and apoptosis, and is thought to play a role in tumour development. Previous prospective studies have shown that higher circulating concentrations of IGF-I are associated with a higher risk of cancers at specific sites, including breast and prostate. No prospective study has examined the association between circulating IGF-I concentrations and melanoma risk. A nested case-control study of 1221 melanoma cases and 1221 controls was performed in the European Prospective Investigation into Cancer and Nutrition cohort, a prospective cohort of 520,000 participants recruited from 10 European countries. Conditional logistic regression was used to estimate odds ratios (ORs) for incident melanoma in relation to circulating IGF-I concentrations, measured by immunoassay. Analyses were conditioned on the matching factors and further adjusted for age at blood collection, education, height, BMI, smoking status, alcohol intake, marital status, physical activity, and in women only, use of menopausal hormone therapy. There was no significant association between circulating IGF-I concentration and melanoma risk (OR for highest vs lowest fifth=0.93 (95% confidence interval (CI): 0.71 to 1.22)). There was no significant heterogeneity in the association between IGF-I concentrations and melanoma risk when subdivided by sex, age at blood collection, BMI, height, age at diagnosis, time between blood collection and diagnosis, or by anatomical site or histological subtype of the tumour (Pheterogeneity≥0.078). We found no evidence for an association between circulating concentrations of IGF-I measured in adulthood and the risk of melanoma. This article is protected by copyright. All rights reserved.

show abstract

Insulin-like growth factor I (CA) repeats are associated with higher melanoma's Breslow index but not associated with the presence of the melanoma. A pilot study

Cited by 9 publications

References 28 publications

Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels with risk of malignant melanoma

Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels with risk of malignant melanoma

Insulin-Like Growth Factor System and Sporadic Malignant Melanoma

Circulating insulin‐like growth factor I in relation to melanoma risk in the European prospective investigation into cancer and nutrition

Contact Info

Product

Resources

About